FRANKFURT (dpa-AFX Broker) - Carl Zeiss Med itec's business outlook on Tuesday further strengthened investors' recently returned confidence. The shares of the medical technology group climbed to the top of the MDax with a double-digit rise in some cases to their highest level since mid-August. At EUR 96.78, the shares almost reached their exponential 200-day line again and reduced their annual loss to 18 percent. At the end of October, it was still 38 percent.

In the early afternoon of Tuesday, the shares were still up 6.8 percent at 93.80 euros.

Although experts were not entirely unanimous in their initial reactions to the targets for 2024, investors were not deterred. For them, the prospect of a stable operating result in the coming year was enough for a further share price recovery.

Earlier this morning, JPMorgan analyst Anchal Verma had predicted a mid-single-digit share price loss. She concluded that the outlook was weak after the 2022/23 financial year had already disappointed.

Other experts were quick to counter this with regard to 2024. "The outlook has more than just delivered," commented Graham Doyle from UBS, for example. Both the sales and margin targets are encouraging in the short term and also positive in terms of profitability in the long term. "There was a certain degree of concern about another warning".

Another UBS analyst sees some headwinds blowing over from the final quarter into the first half of the year. However, this has long since been priced in. The full-year target would then be positive again, including the announced return to the medium-term growth target of more than 20 percent./ag/mis/stk